Early Proof, Real Confidence: integrating patient cohorts early on to secure investment

Welcome to our webinar Early Proof, Real Confidence: Integrating patient cohorts early on to secure investment

Created and presented by Dr. Lila Krebs-Drouot, Head of Medical Affairs at Eurofins Optimed

In a context where drug development is increasingly data-driven and investor expectations for early proof-of-concept are rising, the integration of small patient cohorts from ultra-early phases (Phase 0, combined Phase 1) represents a high-value strategic approach.

This one-hour webinar will provide methodological, operational, and strategic insights into these innovative study designs, from preclinical stages through early regulatory interactions. The focus will be on generating early clinical signals that support development decisions and fundraising activities.

Agenda:

• Overview of ultra-early phases and innovative study designs
• Integration of patient cohorts: scientific and methodological rationale
• Investor perspective: early clinical signal generation and risk reduction
• Data-driven development pathways: from preclinical to submission
• Q&A session